Overview

Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery

Status:
Terminated

Trial end date:
2016-05-01

Target enrollment:

Participant gender:

Summary

This phase I trial studies the side effects and the safety of injecting HSV1716 (a new experimental therapy) into or near the tumor resection cavity. The injection will be done at the time of surgery. HSV1716 is a virus that has a gene which has been changed or removed (mutated) in such a way that lets the virus multiply in dividing cells of the tumor and kills the tumor cells.

Phase:

Phase 1

Details

Lead Sponsor:

Pediatric Brain Tumor Consortium

Collaborator:

National Cancer Institute (NCI)

Treatments:

BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate